Hillege, H. L. et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113, 671–678 (2006).

Article  PubMed  Google Scholar 

Damman, K. et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur. Heart J. 35, 455–469 (2014).

Article  PubMed  Google Scholar 

Damman, K. & Testani, J. M. The kidney in heart failure: an update. Eur. Heart J. 36, 1437–1444 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Löfman, I., Szummer, K., Dahlström, U., Jernberg, T. & Lund, L. H. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur. J. Heart Fail. 19, 1606–1614 (2017).

Article  PubMed  Google Scholar 

Gheorghiade, M. et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am. J. Cardiol. 96, 11G–17G (2005).

Article  PubMed  Google Scholar 

Schefold, J. C., Filippatos, G., Hasenfuss, G., Anker, S. D. & von Haehling, S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat. Rev. Nephrol. 12, 610–623 (2016).

Article  CAS  PubMed  Google Scholar 

Mullens, W. et al. Evaluation of kidney function throughout the heart failure trajectory—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 22, 584–603 (2020).

Article  PubMed  Google Scholar 

McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599–3726 (2021).

Article  CAS  PubMed  Google Scholar 

Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, e895–e1032 (2022).

PubMed  Google Scholar 

CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316, 1429–1435 (1987).

Article  Google Scholar 

Yusuf, S. et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293–302 (1991).

Article  PubMed  Google Scholar 

Yusuf, S. et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327, 685–691 (1992).

Article  CAS  PubMed  Google Scholar 

Pfeffer, M. A. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362, 759–766 (2003).

Article  CAS  PubMed  Google Scholar 

Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709–717 (1999).

Article  CAS  PubMed  Google Scholar 

Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11–21 (2011).

Article  CAS  PubMed  Google Scholar 

McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993–1004 (2014).

Article  PubMed  Google Scholar 

Solomon, S. D. et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 381, 1609–1620 (2019).

Article  CAS  PubMed  Google Scholar 

Mehra, M. R. et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J. Heart Lung Transpl. 35, 1–23 (2016).

Article  Google Scholar 

Damman, K. et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 6, 489–498 (2018).

Article  PubMed  Google Scholar 

Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).

Article  CAS  PubMed  Google Scholar 

Jhund, P. S. et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation 143, 298–309 (2021).

Article  CAS  PubMed  Google Scholar 

Mc Causland, F. R. et al. Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial. JAMA Cardiol. 8, 56–65 (2023).

Article  PubMed  Google Scholar 

Sharma, A. et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial. Eur. J. Heart Fail. 25, 1337–1348 (2023).

Article  CAS  PubMed  Google Scholar 

Inker, L. A. et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J. Am. Soc. Nephrol. 30, 1735–1745 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lambers Heerspink, H. J. et al. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am. J. Kidney Dis. 63, 244–250 (2014).

Article  CAS  PubMed  Google Scholar 

Inker, L. A. et al. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am. J. Kidney Dis. 64, 848–859 (2014).

Article  PubMed  Google Scholar 

Pocock, S. J., Ariti, C. A., Collier, T. J. & Wang, D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur. Heart J. 33, 176–182 (2012).

Article  PubMed  Google Scholar 

Redfors, B. et al. The win ratio approach for composite endpoints: practical guidance based on previous experience. Eur. Heart J. 41, 4391–4399 (2020).

Article  PubMed  Google Scholar 

Little, D. J. et al. Validity and utility of a hierarchical composite end point for clinical trials of kidney disease progression: a review. J. Am. Soc. Nephrol. 34, 1928–1935 (2023).

Article  PubMed  Google Scholar 

Heerspink, H. J. L. et al. Development and validation of a new hierarchical composite end point for clinical trials of kidney disease progression. J. Am. Soc. Nephrol. 34, 2025–2038 (2023).

Article  PubMed  Google Scholar 

McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).

Article  CAS  PubMed  Google Scholar 

Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089–1098 (2022).

Article  PubMed  Google Scholar 

Packer, M. et al. Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. Eur. J. Heart Fail. 23, 1798–1799 (2021).

Article  CAS  PubMed  Google Scholar 

Adamson, C. et al. Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation 146, 438–449 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chatur, S. et al. Variation in renal function following transition to sacubitril/valsartan in patients with heart failure. J. Am. Coll. Cardiol. 81, 1443–1455 (2023).

Article  CAS  PubMed  Google Scholar 

Packer, M. Pitfalls in using estimated glomerular filtration rate slope as a surrogate for the effect of drugs on the risk of serious adverse renal outcomes in clinical trials of patients with heart failure. Circ. Heart Fail. 14, e008537 (2021).

Article  PubMed  Google Scholar 

Inker, L. A. et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat. Med. 29, 1867–1876 (2023).

Article  CAS  PubMed  Google Scholar 

Vonesh, E. et al. Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. Stat. Med. 38, 4218–4239 (2019).

Article  PubMed  Google Scholar 

McMurray, J. J. V. et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur. J. Heart Fail. 21, 665–675 (2019).

Article  CAS  PubMed  Google Scholar